ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,030 | -70.1% | 85 | -61.4% | 0.00% | -100.0% |
| Q2 2023 | $10,149 | +31.8% | 220 | +14.6% | 0.00% | 0.0% |
| Q1 2023 | $7,699 | -62.2% | 192 | -56.4% | 0.00% | -66.7% |
| Q4 2022 | $20,385 | +307.7% | 440 | +286.0% | 0.00% | +200.0% |
| Q3 2022 | $5,000 | +150.0% | 114 | +307.1% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 28 | +16.7% | 0.00% | – |
| Q4 2021 | $2,000 | +100.0% | 24 | +242.9% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 7 | -58.8% | 0.00% | – |
| Q4 2019 | $1,000 | -75.0% | 17 | -80.5% | 0.00% | -100.0% |
| Q3 2019 | $4,000 | 0.0% | 87 | +38.1% | 0.00% | 0.0% |
| Q2 2019 | $4,000 | 0.0% | 63 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $4,000 | +100.0% | 63 | 0.0% | 0.00% | +100.0% |
| Q4 2018 | $2,000 | – | 63 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |